Last $2.65 USD
Change Today +0.03 / 1.15%
Volume 1.2M
SZYM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

solazyme inc (SZYM) Snapshot

Open
$2.64
Previous Close
$2.62
Day High
$2.70
Day Low
$2.59
52 Week High
03/12/14 - $15.00
52 Week Low
11/25/14 - $2.59
Market Cap
210.1M
Average Volume 10 Days
1.9M
EPS TTM
$-2.02
Shares Outstanding
79.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOLAZYME INC (SZYM)

solazyme inc (SZYM) Related Businessweek News

View More BusinessWeek News

solazyme inc (SZYM) Details

Solazyme, Inc. manufactures and sells renewable oils and other bioproducts. Its proprietary technology transforms a range of plant-based sugars into triglyceride oils and other bioproducts. The company offers renewable tailored oils, such as oleic oils that provide sustainable solutions within the food, lubricant, functional fluid, and oleo chemical markets; and drop-in replacements and blend stocks for marine, motor vehicle and jet fuels, as well as replacements for petrochemicals. It is also provides fuels, including SoladieselBD, a fatty acid methyl ester; SoladieselRD, a hydro-treated renewable diesel; SoladieselHRD-76, a military grade hydrotreated renewable diesel; and SolajetD7566 and SolajetHRJ-5 that are commercial and military grade hydrotreated renewable jets. In addition, the company offers microalgae-based food ingredients consisting of tailored oils and whole algal powders that enhance the nutritional profile and functionality of food products; and powdered ingredients comprising whole algal flour, whole algal protein, and golden chlorella high protein. Additionally, it provides skin and personal care products under the Algenist brand name, which include concentrated reconstructing serum, an anti-aging serum; complete eye renewal balm; firming and lifting cream, an anti-aging moisturizing cream; advanced anti-aging repairing oil, a face oil formulation; and genius cream. The company was incorporated in 2003 and is headquartered in South San Francisco, California.

271 Employees
Last Reported Date: 03/14/14
Founded in 2003

solazyme inc (SZYM) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $545.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $360.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $321.4K
Chief Technology Officer
Total Annual Compensation: $360.7K
Strategic Advisor
Total Annual Compensation: $412.0K
Compensation as of Fiscal Year 2013.

solazyme inc (SZYM) Key Developments

Solazyme Launches Partnership with Versalis to Commercialize Encapso(TM)

Solazyme, Inc. and Versalis, the chemical subsidiary of Eni S.p.A. announced a partnership to expand the commercial use of Encapso(TM) - the commercially-available, biodegradable encapsulated lubricant for drilling fluids. Versalis will expand market access and drive global sales for Encapso as a high-performance and sustainable drilling fluid additive. Versalis' initial emphasis for Encapso will be oil and gas fields operated by its parent company Eni, which represent a significant amount of the world's petroleum drilling activity. Encapso will be featured as part of the company's recently launched Specialty Oilfield Chemicals product portfolio with target sales volumes exceeding 3,000 metric tons of Encapso annually.

Solazyme, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Capex Guidance for the Full Year of 2014

Solazyme, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. Total revenue was $17.6 million compared with $10.6 million in the third quarter of 2013, an increase of 65%. GAAP net loss was $39.7 million, which compares with net loss of $30.7 million in the prior year period. On a non-GAAP basis, the net loss was $35.3 million compared with $22.3 million in the prior year quarter. Gaap net loss per share was $0.50 against $0.47 per share reported last year. Loss from operations was $35,493,000 compared to $24,093,000 a year ago. Net loss (non-GAAP) per share was at $0.45 compared to $0.34 a year ago. For the nine months period, the company reported total revenues of $45,889,000 compared to $28,476,000 a year ago. Loss from operations was $100,166,000 compared to $68,125,000 a year ago. Net loss was $117,275,000 or $1.57 per basic and diluted share compared to $83,053,000 or $1.32 per basic and diluted share a year ago. Net loss (non-GAAP) was $97,881,000 or $1.31 per share compared to $61,136,000 or $0.97 per share a year ago. The company provided capex guidance for the full year of 2014. For the year 2014 the company is currently anticipating total revenue to come in a bit north of $60 million or up more than 50% from 2013. CapEx is anticipated to be slightly below $10 million.

Solazyme Names David Cole as Strategic Advisor

Solazyme reported that President David Cole is transitioning from an executive operational role back to the advisory role he occupied prior to January. According to a company release, His advisory responsibilities will be broadened to include leadership of the company's strategic advisory boards. Cole will be stepping down from the Board of Directors as part of the transition.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SZYM:US $2.65 USD +0.03

SZYM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amyris Inc $3.01 USD -0.05
Gevo Inc $0.50 USD +0.008
Koninklijke Wessanen NV €5.37 EUR +0.041
Pacific Ethanol Inc $13.37 USD -0.53
View Industry Companies
 

Industry Analysis

SZYM

Industry Average

Valuation SZYM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOLAZYME INC, please visit www.solazyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.